The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 04, 2020

Filed:

Jun. 28, 2017
Applicants:

TG Therapeutics, Inc., New York, NY (US);

Rhizen Pharmaceuticals SA, La Chaux de Fonds, CH;

Laboratoire Francais Du Fractionnement ET Des Biotechnologies, Les Ulis, FR;

Inventors:

Michael S. Weiss, New York, NY (US);

Hari P. Miskin, New York, NY (US);

Peter Sportelli, New York, NY (US);

Swaroop K. V. S. Vakkalanka, La Chaux de Fonds, CH;

Assignees:
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); A61K 31/519 (2006.01); C07K 16/28 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
A61K 39/3955 (2013.01); A61K 31/519 (2013.01); A61K 45/06 (2013.01); C07K 16/2887 (2013.01); C07K 2317/24 (2013.01); C07K 2317/73 (2013.01);
Abstract

Highly effective combinations of a compound of formula A (a PI3Kδ selective inhibitor) and anti-CD20 antibodies are provided herein for the treatment and amelioration of PI3Kδ and/or CD20 mediated diseases and disorderes. In particular, the combination can be used to treat cancers and autoimmune diseases. More particularly, the invention provided for a combination of a compound of formula A, or stereoisomers thereof, and ublituximab for the treatment and/or amerioration of hematological malignancies such as leukemia and lymphoma.


Find Patent Forward Citations

Loading…